Revolab, a success story powered by EIT Digital Venture Program

Lithuanian startup Revolab, a winner of the 2020 EIT Digital Venture Program that has developed a platform to keep track of users overall physical wellbeing via a home blood test kit, is forging ahead at a remarkable pace.

In a record time of one year, the company came from inception to closing a seed round in May, signing €100K of pre-orders, and now achieving CE certification for its products, enabling sales across Europe.

Following simple step-by-step instructions, users collect a finger-prick blood sample and ship it back to Revolab. The results are available within 24 hours on the app.

More than 30 different blood work tests are currently available such as complete blood count (CBC), glucose level, thyroid panels, STD tests or enzyme markers if you are at risk of cancer or other conditions. Special blood work tests, such as for vegans and vegetarians, are also available, which check for missing key nutrients.

The pandemic accelerated the adoption of self-tests allowing people to take charge of their own health, especially the ones with chronic diseases such as diabetes, high cholesterol or cancer predisposition, making Revolab’s value proposition even more compelling.